|
 The Pfizer drug, to be sold under the name Inflectra, is already
available in Europe and other overseas markets and would be the
second biosimilar medicine available in the United States.
As it is not possible to produce exact copies of biotech drugs made
from living cells, the cheaper versions - referred to as biosimilars
rather than generics - are intended to provide cost savings compared
with pricey biologic medicines.
Remicade is J&J's biggest selling drug with U.S. sales of about $5
billion a year.
J&J's forecasts for 2016 had assumed no competition from a Remicade
biosimilar this year. Its shares slipped nearly 0.5 percent to
$118.00 in after-hours trading.
J&J said in an emailed statement that it considers any sales by
Pfizer of a Remicade biosimilar to be an "at risk launch." That
could entitle the company to triple damages if Pfizer is found in
court to have infringed Remicade patents.
A Pfizer spokeswoman said the company could not comment on ongoing
litigation.
Pfizer's pricing for the drug below Remicade wholesale costs does
not take into account discounts to health insurers, distributors or
other purchasing organizations, the company said.
JP Morgan analyst Michael Weinstein, in a research note, forecast a
Remicade revenue decline of just over $1 billion in 2017, costing
J&J 20 cents in earnings per share.
"Inflectra's 15 percent discount should provide enough of an
incentive to help attract new patients ... but probably won’t be
enough of a discount to entice stable patients to switch over,"
Weinstein said.
J&J said it expects to be competitive with the Remicade biosimilar.
[to top of second column] |
"We intend to compete through a variety of innovative contracting
options, discounts and rebates to payers, providers and pharmacy
benefit managers to ensure Remicade remains an affordable option for
patients and physicians," a J&J statement said.
In addition to rheumatoid arthritis Inflectra, like Remicade, is
also approved to treat Crohn's disease, ulcerative colitis,
psoriasis, psoriatic arthritis and the spine condition ankylosing
spondylitits.
Novartis <NOVN.S> last year began selling the first biosimilar in
the United States, a cheaper version of Amgen's <AMGN.O> infection
fighter Neupogen called Zarxio.
Several companies are developing biosimilar versions of the
top-selling biotech medicines for rheumatoid arthritis and cancer.
(Reporting by Bill Berkrot and Ransdell Pierson; editing by Bernard
Orr, G Crosse)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
